|Articles|May 10, 2017
Japanese Firm Selects iCardiac for Oncology Trial
iCardiac announced that it has been selected to work on an early phase oncology clinical trial with a global Japanese pharma company.
Advertisement
iCardiac announced that it has been selected to work on an early phase oncology clinical trial with a global Japanese pharma company. This study will utilize iCardiac’s Rapid QT service offering, which assists trial sites in making accurate patient inclusion/exclusion decisions.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
Everything to Know About FDA’s Push Towards Radical Transparency in 2025September 17th 2025
IQVIA and Veeva Join Forces to Improve Efficiency and Patient OutcomesSeptember 17th 2025
Managing Background Therapies in the NIMBLE Phase III TrialSeptember 17th 2025
Generative AI Transforms Clinical Study Report DevelopmentSeptember 16th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Everything to Know About FDA’s Push Towards Radical Transparency in 2025
2
Generative AI Transforms Clinical Study Report Development
3
Why Clinical Trials Are at a Crossroads and How Site Networks Are the Key to Success
4
IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
